Borrow it

The Resource Population Assessment of Tobacco and Health (PATH) Study [United States] Biomarker Restricted-Use Files

Population Assessment of Tobacco and Health (PATH) Study [United States] Biomarker Restricted-Use Files

Resource Information

The item Population Assessment of Tobacco and Health (PATH) Study [United States] Biomarker Restricted-Use Files represents a specific, individual, material embodiment of a distinct intellectual or artistic creation found in Bowdoin College Library.
This item is available to borrow from 1 library branch.

Creator

Author

Contributor

United States Department of Health and Human Services. Food and Drug Administration. Center for Tobacco Products

Summary: The Population Assessment of Tobacco and Health (PATH) Study is a collaboration between the National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), and the Center for Tobacco Products (CTP), Food and Drug Administration (FDA). The study was launched in 2011 to inform the FDA's tobacco regulatory activities under the <a href="https://www.fda.gov/tobacco-products/rules-regulations-and-guidance/family-smoking-prevention-and-tobacco-control-act-table-contents">Family Smoking Prevention and Tobacco Control Act (TCA)</a>. For Wave 1 (baseline), the PATH Study sampled over 150,000 mailing addresses across the United States to create a national sample of tobacco users and non-users, yielding interviews with 45,971 adult and youth respondents. 45,971 adults and youth constitute the first (baseline) wave, Wave 1, of data collected by this longitudinal cohort study. These 45,971 adults and youth along with 7,207 "shadow youth" (youth ages 9 to 11 sampled at Wave 1) make up the 53,178 participants that constitute the Wave 1 Cohort. Respondents are asked to complete an interview at each follow-up wave. Youth who turn 18 by the current wave of data collection are considered "aged-up adults" and are invited to complete the Adult Interview. Additionally, "shadow youth" are considered "aged-up youth" upon turning 12 years old, when they are asked to complete an interview after parental consent.At Wave 4, a probability sample of 14,098 adults, youth, and shadow youth ages 10 to 11 was selected from the civilian, noninstitutionalized population at the time of Wave 4. This sample was recruited from residential addresses not selected for Wave 1 in the same sampled PSUs and segments using similar within-household sampling procedures. This "replenishment sample" was combined for estimation and analysis purposes with Wave 4 adult and youth respondents from the Wave 1 Cohort who were in the civilian, noninstitutionalized population at the time of Wave 4. This combined set of Wave 4 participants, 52,731 participants in total, forms the Wave 4 Cohort.Please refer to the Restricted-Use Files User Guide that provides further details about children designated as "shadow youth" and the formation of the Wave 1 and Wave 4 Cohorts. Each adult respondent, who completed the interview at Wave 1, was asked to provide at least two biospecimens. Providing biospecimens was voluntary and was not a condition of participation. Respondents were asked to report their use of all nicotine-containing products during the 3-day period prior to the time of any biospecimen collection (Nicotine Exposure Questions (NEQs)) to facilitate interpretation of biomarker results. Of the 32,320 respondents who completed the adult interview at Wave 1, 21,801 (67.4 percent) provided a urine specimen and 14,520 (44.9 percent) provided a blood specimen. A sample of 11,522 adults who provided sufficient urine for the planned analyses were selected from a diverse mix of six tobacco product use groups representing never, current, and recent former (within 12 months) users of tobacco products. This group constitutes the Wave 1 Biomarker Core. Of the 11,522 adults, 7,159 also provided a blood specimen. All urine and blood specimens provided by the Wave 1 Biomarker Core were sent for laboratory analysis. Wave 1 Restricted-Use Biomarker Data Files (Biomarker RUF) consist of three different types of files: <list type="bulleted"> <itm>2 Collection and NEQ files for Urine (DS1001) and Blood (DS1101)</itm> <itm>2 Biomarker Weight files including variables for use in variance estimation for Urine (DS1021) and Blood (DS1121)</itm> <itm>8 Urine Panels (DS1031 to DS1038), 4 Serum Panels (DS1131 to DS1134) and 1 Plasma Panel (DS1231) containing biomarker assay results.</itm> </list> For Wave 2, urine biospecimens were requested from the Wave 1 Biomarker Core. Respondents were also asked to complete the NEQs prior to biospecimen collection. The Wave 2 Biomarker RUF consists of three different types of files: <list type="bulleted"> <itm>1 Collection and NEQ file for Urine (DS2001)</itm> <itm>2 Biomarker Weight files including variables for use in variance estimation for Urine (DS2021) and F2PG2a (DS2022)</itm> <itm>8 Urine Panels (DS2031 to DS2038) containing biomarker assay results.</itm> </list> For Wave 3, urine biospecimens were requested from the Wave 1 Biomarker Core. Respondents were also asked to complete the NEQs prior to biospecimen collection. The Wave 3 Biomarker RUF consists of three different types of files: <list type="bulleted"> <itm>1 Collection and NEQ file for Urine (DS3001)</itm> <itm>2 Biomarker Weight files including variables for use in variance estimation for Urine (DS3021 and DS3022)</itm> <itm>6 Urine Panels (DS3032 to DS3037) containing biomarker assay results. Additional panel(s) will be added at a later date.</itm> </list> For Wave 4, urine biospecimens were requested from the Wave 1 Biomarker Core. Respondents were also asked to complete the NEQs prior to biospecimen collection. The Wave 4 Biomarker RUF consists of three different types of files: <list type="bulleted"> <itm>1 Collection and NEQ file for Urine (DS4001)</itm> <itm>2 Biomarker Weight files including variables for use in variance estimation for Urine (DS4021 and DS4022)</itm> <itm>5 Urine Panels (DS4032, DS4033, DS4035, DS4036 and DS4037) containing biomarker assay results. Additional panel(s) will be added at a later date.</itm> </list> References to the collection of biospecimens will be specified by the collected specimen, i.e., urine and (whole) blood. However, references to biomarker analyses and analytes will be specified by the type of matrix (serum, plasma, or urine) used for the analysis

Work

Publication

06-03-2021

Note

2013--2014
2014--2015
2015--2016
2016--2018
36840

Instance

Label: Population Assessment of Tobacco and Health (PATH) Study [United States] Biomarker Restricted-Use Files

Title: Population Assessment of Tobacco and Health (PATH) Study [United States] Biomarker Restricted-Use Files

Creator

Contributor

United States Department of Health and Human Services. Food and Drug Administration. Center for Tobacco Products

Author

Contributor

Inter-university Consortium for Political and Social Research [distributor]

Subject

Genre

Summary: The Population Assessment of Tobacco and Health (PATH) Study is a collaboration between the National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), and the Center for Tobacco Products (CTP), Food and Drug Administration (FDA). The study was launched in 2011 to inform the FDA's tobacco regulatory activities under the <a href="https://www.fda.gov/tobacco-products/rules-regulations-and-guidance/family-smoking-prevention-and-tobacco-control-act-table-contents">Family Smoking Prevention and Tobacco Control Act (TCA)</a>. For Wave 1 (baseline), the PATH Study sampled over 150,000 mailing addresses across the United States to create a national sample of tobacco users and non-users, yielding interviews with 45,971 adult and youth respondents. 45,971 adults and youth constitute the first (baseline) wave, Wave 1, of data collected by this longitudinal cohort study. These 45,971 adults and youth along with 7,207 "shadow youth" (youth ages 9 to 11 sampled at Wave 1) make up the 53,178 participants that constitute the Wave 1 Cohort. Respondents are asked to complete an interview at each follow-up wave. Youth who turn 18 by the current wave of data collection are considered "aged-up adults" and are invited to complete the Adult Interview. Additionally, "shadow youth" are considered "aged-up youth" upon turning 12 years old, when they are asked to complete an interview after parental consent.At Wave 4, a probability sample of 14,098 adults, youth, and shadow youth ages 10 to 11 was selected from the civilian, noninstitutionalized population at the time of Wave 4. This sample was recruited from residential addresses not selected for Wave 1 in the same sampled PSUs and segments using similar within-household sampling procedures. This "replenishment sample" was combined for estimation and analysis purposes with Wave 4 adult and youth respondents from the Wave 1 Cohort who were in the civilian, noninstitutionalized population at the time of Wave 4. This combined set of Wave 4 participants, 52,731 participants in total, forms the Wave 4 Cohort.Please refer to the Restricted-Use Files User Guide that provides further details about children designated as "shadow youth" and the formation of the Wave 1 and Wave 4 Cohorts. Each adult respondent, who completed the interview at Wave 1, was asked to provide at least two biospecimens. Providing biospecimens was voluntary and was not a condition of participation. Respondents were asked to report their use of all nicotine-containing products during the 3-day period prior to the time of any biospecimen collection (Nicotine Exposure Questions (NEQs)) to facilitate interpretation of biomarker results. Of the 32,320 respondents who completed the adult interview at Wave 1, 21,801 (67.4 percent) provided a urine specimen and 14,520 (44.9 percent) provided a blood specimen. A sample of 11,522 adults who provided sufficient urine for the planned analyses were selected from a diverse mix of six tobacco product use groups representing never, current, and recent former (within 12 months) users of tobacco products. This group constitutes the Wave 1 Biomarker Core. Of the 11,522 adults, 7,159 also provided a blood specimen. All urine and blood specimens provided by the Wave 1 Biomarker Core were sent for laboratory analysis. Wave 1 Restricted-Use Biomarker Data Files (Biomarker RUF) consist of three different types of files: <list type="bulleted"> <itm>2 Collection and NEQ files for Urine (DS1001) and Blood (DS1101)</itm> <itm>2 Biomarker Weight files including variables for use in variance estimation for Urine (DS1021) and Blood (DS1121)</itm> <itm>8 Urine Panels (DS1031 to DS1038), 4 Serum Panels (DS1131 to DS1134) and 1 Plasma Panel (DS1231) containing biomarker assay results.</itm> </list> For Wave 2, urine biospecimens were requested from the Wave 1 Biomarker Core. Respondents were also asked to complete the NEQs prior to biospecimen collection. The Wave 2 Biomarker RUF consists of three different types of files: <list type="bulleted"> <itm>1 Collection and NEQ file for Urine (DS2001)</itm> <itm>2 Biomarker Weight files including variables for use in variance estimation for Urine (DS2021) and F2PG2a (DS2022)</itm> <itm>8 Urine Panels (DS2031 to DS2038) containing biomarker assay results.</itm> </list> For Wave 3, urine biospecimens were requested from the Wave 1 Biomarker Core. Respondents were also asked to complete the NEQs prior to biospecimen collection. The Wave 3 Biomarker RUF consists of three different types of files: <list type="bulleted"> <itm>1 Collection and NEQ file for Urine (DS3001)</itm> <itm>2 Biomarker Weight files including variables for use in variance estimation for Urine (DS3021 and DS3022)</itm> <itm>6 Urine Panels (DS3032 to DS3037) containing biomarker assay results. Additional panel(s) will be added at a later date.</itm> </list> For Wave 4, urine biospecimens were requested from the Wave 1 Biomarker Core. Respondents were also asked to complete the NEQs prior to biospecimen collection. The Wave 4 Biomarker RUF consists of three different types of files: <list type="bulleted"> <itm>1 Collection and NEQ file for Urine (DS4001)</itm> <itm>2 Biomarker Weight files including variables for use in variance estimation for Urine (DS4021 and DS4022)</itm> <itm>5 Urine Panels (DS4032, DS4033, DS4035, DS4036 and DS4037) containing biomarker assay results. Additional panel(s) will be added at a later date.</itm> </list> References to the collection of biospecimens will be specified by the collected specimen, i.e., urine and (whole) blood. However, references to biomarker analyses and analytes will be specified by the type of matrix (serum, plasma, or urine) used for the analysis

http://library.link/vocab/creatorName

United States Department of Health and Human Services. National Institutes of Health. National Institute on Drug Abuse
Inter-university Consortium for Political and Social Research [distributor]

http://library.link/vocab/relatedWorkOrContributorName: United States Department of Health and Human Services. Food and Drug Administration. Center for Tobacco Products